Bouvel Investment Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.19M Sell
6,825
-64
-0.9% -$65.4K 1.85% 21
2026
Q1
$6.34M Buy
6,889
+71
+1% +$72K 1.84% 20
2025
Q4
$7.33M Buy
6,818
+90
+1% +$86.1K 2.11% 12
2025
Q3
$5.13M Sell
6,728
-9
-0.1% -$6.7K 1.57% 26
2025
Q2
$5.25M Buy
6,737
+199
+3% +$155K 1.78% 22
2025
Q1
$5.79M Sell
6,538
-106
-2% -$88.2K 2.18% 12
2024
Q4
$5.13M Buy
6,644
+106
+2% +$87.8K 1.85% 18
2024
Q3
$5.79M Buy
6,538
+37
+0.6% +$33.3K 2.18% 12
2024
Q2
$5.89M Buy
6,501
+42
+0.7% +$33.6K 2.28% 12
2024
Q1
$5.02M Buy
6,459
+2,313
+56% +$1.65M 2.17% 15
2023
Q4
$2.42M Buy
4,146
+189
+5% +$110K 1.13% 39
2023
Q3
$2.13M Buy
+3,957
New +$2.04M 1.15% 39

Other funds holding LLY

Bouvel Investment Partners's LLY Position: Q2 2026 in Review

Bouvel Investment Partners reduced its Eli Lilly (LLY) stake by 0.93% in Q2 2026, selling an estimated $65.4K and leaving 6,825 shares worth $8.19M. The position accounts for 1.85% of the portfolio, ranked #21.

Bouvel Investment Partners first reported a position in LLY in Q3 2023 and has held it in 12 quarters since. 961 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Bouvel Investment Partners held 6,825 shares of Eli Lilly worth $8.19M as of Q2 2026.
  • Bouvel Investment Partners sold 64 Eli Lilly shares in Q2 2026, an estimated $65.4K.
  • Eli Lilly made up 1.85% of Bouvel Investment Partners's portfolio in Q2 2026, its #21 holding.
  • Bouvel Investment Partners first reported a position in Eli Lilly in Q3 2023 and has held it in 12 quarters since.
  • 961 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Bouvel Investment Partners's 13F filing for Q2 2026, filed 17 Jul 2026.